Limits of confidence in tracer compounds as a means of measuring patient compliance with medication

Journal of Clinical Pharmacology

Volumn 39, Issue 12, 1999, Pages 1233-1241

  Shine, D ^a   McDonald, J ^a  

^a MONMOUTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MARKER; PHENOBARBITAL;

ARTICLE; CURVE FITTING; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MATHEMATICAL COMPUTING; MODEL; NORMAL HUMAN; PATIENT COMPLIANCE; SIGNAL NOISE RATIO; STANDARD;

EID: 0033307293     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922012033     Document Type: Article

References (30)

1. Evaluation and recommendations for adherence marker development by working groups of the workshop
2. The natural history of medication compliance in a drug trial: Limitations of pill counts
3. Biochemical markers of compliance in the physicians' health study
4. Compliance with medication in the Helsinki heart study
5. Overview of methods to measure and enhance patient compliance
6. The impact of patient compliance on drug concentration profile in multiple doses
7. Measuring intake of a prescribed medication bottle count and a tracer technique compared
8. Detection methods and strategies for improving medication compliance
9. Comparison of the digoxin marker with capsule counting and compliance to medication in a clinical trial
10. Improved compliance measures: Applications in an ambulatory hypertensive drug trial
11. Use of electronic pill boxes to asses risk of poor treatment compliance: Results of a large-scale trial
12. Electronic compliance assessment of antifungal prophylaxis human immunodeficiency virus-infected women
13. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device
14. Enhancing patient compliance in the elderly: Role of packaging aids and monitoring
15. Statement of the problem and pharmacological and clinical requirements for the ideal marker
16. In search of the gold standard for compliance measurement
17. Compliance during tricyclic antidepressant therapy: Pharmacokinetic and analytical issues
18. Use of p-aminobenzoic acid to monitor compliance with prescribed dietary regimens during metabolic balance studies in man
19. Assessment of theophylline compliance in general practice using a 'compliance index' based on apparent drug clearance
20. Compliance and variability of plasma phenytoin levels in epileptic patients
21. Compliant populations: Variability in serum concentrations
22. Assessing drug compliance using longitudinal marker data, with application to AIDS
23. A comparison of short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone), and measurements of a controlled released 'therapeutic drug' (metoprolol, motoros) in reflecting incomplete compliance by volunteers
24. The prediction of steady state plasma phenobarbitone concentrations (following low dose phenobarbitone) to refine use as an indicator of compliance
25. Measurement of low (sub-therapeutic) phenobarbitone levels in plasma by high-performance liquid chromatography: Application to patient compliance studies
26. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily
27. Plasma levels of phenobarbital and phenytoin in epileptic outpatients
28. Use of a 'very low-dose phenobarbital' to investigate compliance in patients on reducing doses of methadone
29. A computer model for the measurement of compliance using a dual tracer technique
30. Compliance declines between clinic visits